Cassava: Low-Cost Pivot Into TSC Epilepsy Is Unlikely To Create Long-Term Value
Cassava's strong liquidity with $128.6 million in cash supports early-stage development, yet long-term funding needs may lead ...
Cassava Sciences Licenses Simufilam Method of Treatment Patent
Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with simufilam o ...
Business Insider11d
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
“Cassava is preparing to report the topline results of the now-discontinued REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, in late first-quarter/early second-quarter 2025.
Lao government seeks larger niche in global cassava market
VIENTIANE: The government plans to increase crop yields, upgrade processing plants, and expand the export market with a view ...
Business Insider15d
Cassava Sciences Licenses Simufilam Method of Treatment Patent
Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with ...